New hope against deadly mold infections: generic drug shows promise
NCT ID NCT07239765
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a generic version of an antifungal drug called Amphotericin B Cholesteryl Sulfate Complex (ABCD) in 67 adults with invasive mold disease, a serious infection. The goal was to see if the drug is safe and works well. Participants received the drug through an IV, and researchers tracked side effects and how many completed treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Amphotericin B Cholesteryl Sulfate Complex (ABCD)
- What this could lead to
- If successful, this could provide a new generic treatment option for serious mold infections, potentially improving access and outcomes.
- What could go wrong
- This is a completed Phase 3 trial with only 67 participants, so results may not apply to all patients. Amphotericin B can cause kidney problems and infusion reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE MOLD DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital Of Guangzhou Medical University
Guangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.